A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.